The preparation of dipalladium complexes containing sterically nondemanding diphosphine (P-P) ligands of the type R(2)PCH(2)PR(2) where R = Me (dmpm) or Et (depm) is reported. Variable-temperature (1)H NMR spectra of the Pd(I)(2) complexes Pd(2)X(2)(dmpm)(2) (X = Cl, Br, or I; the P-P ligands in the Pd(2) complexes are always bridged, but for convenience, the micro -symbol is omitted) show the complexes to be fluxional in solution, the barriers to a ring-flipping process being DeltaG( double dagger ) = 37.9, 39.0, and 43.2 +/- 0.9 kJ mol(-)(1) for the chloro, bromo, and iodo complexes, respectively. Treatment of Pd(2)X(2)(P-P)(2) (X = Cl or Br) with X(2) generates the stable, face-to-face Pd(II)(2) derivatives trans-Pd(2)X(4)(P-P)(2), while oxidation of Pd(2)I(2)(P-P)(2) complexes with I(2) generates a new type of symmetrically di-iodo-bridged, five-coordinate complexes Pd(2)I(2)(micro -I)(2)(dmpm)(2) and Pd(2)I(2)(micro -I)(2)(depm)(2). The molecular crystal structures of four dipalladium(II) complexes are described: trans-Pd(2)Cl(4)(dmpm)(2).2CHCl(3), trans-Pd(2)Br(4)(dmpm)(2), trans-Pd(2)Cl(4)(depm)(2), and Pd(2)I(2)(micro -I)(2)(dmpm)(2). Solution NMR and UV-vis absorption spectra are consistent with the solid-state structures determined by X-ray diffraction. The stability of the dimeric Pd(II) complexes is attributed primarily to ligand steric factors.
No takes yet. Share an insight, caveat, or question.
Pamplin et al. (2003) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: